Guardant Health to Participate in Upcoming March Investor Conferences
02/17/2023 - 08:00 AM
PALO ALTO, Calif. --(BUSINESS WIRE)--
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences.
Citi 2023 Healthcare Services, MedTech, Tools & HCIT Conference in New York City , NY
Fireside Chat on Wednesday, March 1 st at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time
Cowen 43rd Annual Health Care Conference in Boston, MA
Fireside Chat on Wednesday, March 8 th at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time
Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.guardanthealth.com .
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360® , Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantINFINITY™ tests for advanced-stage cancer, and Guardant Reveal™ for early-stage cancer. The Guardant Health screening portfolio, including the commercially launched Shield™ test, aims to address the needs of individuals eligible for cancer screening. For more information, visit guardanthealth.com and follow the company on LinkedIn and Twitter.
View source version on businesswire.com : https://www.businesswire.com/news/home/20230217005075/en/
Investor Contact:
Alex Kleban
investors@guardanthealth.com
+1 657-254-5417
Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035
Source: Guardant Health, Inc.
Guardant Health Inc
NASDAQ:GH
GH Rankings
#4656 Ranked by Stock Gains
GH Stock Data
Industry
Dental Laboratories
Sector
Manufacturing
Tags
Health Services, Medical/Nursing Services, Manufacturing, Dental Laboratories
About GH
we believe conquering cancer is a big data problem. that’s why we built the world’s leading comprehensive liquid biopsy. this non-invasive tool for accessing and sequencing tumor dna is used by thousands of oncologists to help tens of thousands of advanced cancer patients. we believe the boom in cancer data acquisition we helped launch will drive important discoveries and new products. we’re working on some exciting ones, including in early detection, where the impact on patients can be profound. we’ve raised more than $500 million from investors including sequoia capital, khosla ventures, orbimed, and softbank.